Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA.

N Engl J Med. 1998 Aug 27;339(9):584-90.

2.

Normalization of hematocrit in hemodialysis patients does not affect silent ischemia.

Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ.

Ren Fail. 2000 Mar;22(2):205-11.

PMID:
10803764
3.
4.

Correction of anemia with epoetin alfa in chronic kidney disease.

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators.

N Engl J Med. 2006 Nov 16;355(20):2085-98.

5.
6.

Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.

Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ.

Ren Fail. 2000;22(4):435-44.

PMID:
10901181
7.

A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study.

Bren A, Kandus A, Varl J, Buturović J, Ponikvar R, Kveder R, Primozic S, Ivanovich P.

Artif Organs. 2002 Feb;26(2):91-7.

PMID:
11879235
8.

Current management of anemia in adult hemodialysis patients with end-stage renal disease.

Frankenfield DL, Johnson CA.

Am J Health Syst Pharm. 2002 Mar 1;59(5):429-35.

PMID:
11887409
10.

Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.

McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr; End-Stage Renal Disease Core Indicators Work Group.

Am J Kidney Dis. 2001 May;37(5):E36.

PMID:
11325701
11.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group.

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Oct;24(10):3007. Curr Med Res Opin. 2008 Apr;24(4):1155.

PMID:
18208642
12.

The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.

Berns JS, Fishbane S, Elzein H, Lynn RI, Deoreo PB, Tharpe DL, Meisels IS.

Hemodial Int. 2005 Jul;9(3):255-63.

PMID:
16191075
13.

Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.

Driver PS.

Am J Health Syst Pharm. 1998 Dec 15;55(24 Suppl 4):S12-6.

PMID:
9872688
14.

Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.

Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ.

Am J Kidney Dis. 2002 Dec;40(6):1153-61.

PMID:
12460033
15.

The normal hematocrit study--follow-up.

Besarab A, Goodkin DA, Nissenson AR; Normal Hematocrit Cardiac Trial Authors.

N Engl J Med. 2008 Jan 24;358(4):433-4. doi: 10.1056/NEJMc076523. No abstract available.

16.

Epoetin requirements predict mortality in hemodialysis patients.

Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ.

Am J Kidney Dis. 2004 Nov;44(5):866-76.

PMID:
15492953
17.
18.

A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.

Gaughan WJ, Liss KA, Dunn SR, Mangold AM, Buhsmer JP, Michael B, Burke JF.

Am J Kidney Dis. 1997 Oct;30(4):495-500.

PMID:
9328363
19.

Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.

Haag-Weber M, Vetter A, Thyroff-Friesinger U; INJ-Study Group.

Clin Nephrol. 2009 Nov;72(5):380-90.

PMID:
19863881
20.

Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.

Moran LJ, Carey P, Johnson CA.

Am J Hosp Pharm. 1992 Jun;49(6):1451-4.

PMID:
1529988

Supplemental Content

Support Center